ShareThis Page
Allegheny

Highmark Health, Allegheny Health Network to invest $200 million in cancer care

| Tuesday, June 13, 2017, 10:57 a.m.
Allegheny General Hospital, part of Allegheny Health Network, in Pittsburgh's North Side.
Tribune-Review
Allegheny General Hospital, part of Allegheny Health Network, in Pittsburgh's North Side.

Allegheny Health Network is building an academic cancer center with a hub at Allegheny General Hospital and a half-dozen satellite facilities across Western Pennsylvania as part of an expanding partnership with Johns Hopkins Medicine.

Highmark Health, AHN's parent company, plans to invest $200 million to build the centers over the next two years, Highmark CEO David Holmberg said Tuesday.

The health system plans to locate the cancer center's hub next to Allegheny General Hospital's main entrance and is evaluating locations for four to 10 satellite facilities, Holm­berg said.

Johns Hopkins will become Highmark's “preferred referral partner” for treatment outside Western Pennsylvania, and Highmark will expand referrals to the Baltimore-based system for patients with rare and complex adult and pediatric cancers, the executives said. Highmark patients will gain more access to Johns Hopkins' clinical trials, they said.

Under the time frame Holmberg announced, the cancer center would be finished about the time Highmark patients will lose access to cancer treatment from UPMC under a state-brokered consent decree.

The decree, meant to protect patients as the rival health systems unwind business relationships with one another, preserves Highmark members' access through June 2019 to UPMC Hillman Cancer Center, which has its own academic affiliation with the University of Pittsburgh School of Medicine and has more than 50 satellite centers.

Highmark has invested $1 billion in Allegheny Health Network since forming the seven-hospital system that competes with UPMC in 2013, Holmberg said.

“One of the things that we heard from the community when we took on this journey was that they were concerned about access to care and access was being denied by others,” he said. “And we're here to tell you that that's not OK.”

The cancer center expands a relationship between AHN and Johns Hopkins Medicine that presently includes medical second opinions, genetic testing that is used in cancer immunotherapy and a referral collaboration for bone marrow transplantation for lung and pediatric patients. The partnership covers patients in West Virginia and Delaware in addition to Western Pennsylvania.

The officials said the cancer center would bring 175 jobs to Western Pennsylvania.

Dr. Paul Rothman, CEO of Johns Hopkins Medicine, said collaboration is increasingly important as the science of cancer treatment rapidly advances. Highmark collaborates with Johns Hopkins through a Cancer Collaborative program that ties hospitals in Highmark's networks to a national database regularly updated with the latest treatments by the National Comprehensive Cancer Network.

“There's no field of medicine that I think is changing more rapidly,” Rothman said of cancer treatment.

Wes Venteicher is a Tribune-Review staff writer. Reach him at 412-380-5676, wventeicher@tribweb.com or via Twitter @wesventeicher.

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me